IN2015DN00542A - - Google Patents

Info

Publication number
IN2015DN00542A
IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
Authority
IN
India
Prior art keywords
compositions
disorders
methods
treating
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Wei Wei Chang
Kenneth Sawyer
Original Assignee
Rhodes Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies filed Critical Rhodes Technologies
Publication of IN2015DN00542A publication Critical patent/IN2015DN00542A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IN542DEN2015 2012-07-27 2013-07-26 IN2015DN00542A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US201361756321P 2013-01-24 2013-01-24
PCT/US2013/052264 WO2014018856A1 (fr) 2012-07-27 2013-07-26 Compositions et traitement pour maladies et troubles oculaires

Publications (1)

Publication Number Publication Date
IN2015DN00542A true IN2015DN00542A (fr) 2015-06-26

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
IN542DEN2015 IN2015DN00542A (fr) 2012-07-27 2013-07-26

Country Status (20)

Country Link
US (2) US20150216877A1 (fr)
EP (1) EP2877184B1 (fr)
JP (1) JP6209777B2 (fr)
KR (1) KR102097663B1 (fr)
CN (2) CN107595857A (fr)
AU (1) AU2013295645B2 (fr)
BR (1) BR112015001847A8 (fr)
CA (1) CA2880027C (fr)
DK (1) DK2877184T3 (fr)
ES (1) ES2759781T3 (fr)
HU (1) HUE046963T2 (fr)
IL (1) IL236920B (fr)
IN (1) IN2015DN00542A (fr)
MX (1) MX362185B (fr)
NZ (1) NZ704247A (fr)
PL (1) PL2877184T3 (fr)
PT (1) PT2877184T (fr)
SM (1) SMT201900678T1 (fr)
WO (1) WO2014018856A1 (fr)
ZA (1) ZA201500561B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105188708B (zh) 2013-03-15 2019-06-28 格利亚有限责任公司 颅部的药物递送
WO2015080758A1 (fr) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Procédé et composition destinés au traitement de la kératoconjonctivite sèche modérée à sévère
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3171872B1 (fr) 2014-07-21 2020-11-11 Glia, LLC Méthode de traitement de troubles cognitifs ou émotionnels associés à la radiothérapie ou la chimiothérapie au moyen de cannabinoïdes
EP3174542A4 (fr) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Crème transdermique
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US20100016264A1 (en) 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
EP2482788B1 (fr) * 2009-10-02 2022-12-14 Journey Medical Corporation Compositions de tétracycline à usage topique

Also Published As

Publication number Publication date
KR20150038311A (ko) 2015-04-08
NZ704247A (en) 2018-04-27
BR112015001847A8 (pt) 2021-09-08
EP2877184A1 (fr) 2015-06-03
CN107595857A (zh) 2018-01-19
MX362185B (es) 2019-01-08
ZA201500561B (en) 2016-04-28
PL2877184T3 (pl) 2020-04-30
JP2015524434A (ja) 2015-08-24
BR112015001847A2 (pt) 2017-07-04
AU2013295645B2 (en) 2017-08-24
JP6209777B2 (ja) 2017-10-11
HK1210968A1 (en) 2016-05-13
CA2880027C (fr) 2021-12-07
WO2014018856A1 (fr) 2014-01-30
EP2877184B1 (fr) 2019-09-04
PT2877184T (pt) 2019-12-02
IL236920B (en) 2018-06-28
US9925201B2 (en) 2018-03-27
MX2015001250A (es) 2015-10-22
DK2877184T3 (da) 2019-12-09
ES2759781T3 (es) 2020-05-12
EP2877184A4 (fr) 2016-03-30
KR102097663B1 (ko) 2020-04-06
SMT201900678T1 (it) 2020-03-13
US20170189413A1 (en) 2017-07-06
AU2013295645A1 (en) 2015-02-05
HUE046963T2 (hu) 2020-04-28
CA2880027A1 (fr) 2014-01-30
CN104661663A (zh) 2015-05-27
US20150216877A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EP4450130A3 (fr) Formulations d'enzalutamide
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EP3185876A4 (fr) Compositions et procédés de traitement de troubles neurologiques
EP2709672A4 (fr) Compositions et méthodes pour le traitement de maladies de la rétine
EP3212226A4 (fr) Compositions et leurs méthodes d'utilisation pour le traitement de troubles métaboliques
EP3024497A4 (fr) Procédés et compositions pour traiter des maladies du cerveau
EP3174894A4 (fr) Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques
HK1216175A1 (zh) 治療性化合物和組合物
IN2014DN10386A (fr)
EP3160493A4 (fr) Compositions et procédés pour réguler la rénalase dans le traitement de certaines maladies et de certains troubles
EP3182977A4 (fr) Compositions et procédés pour traiter des troubles de la vision
EP2782566A4 (fr) Compositions de l-sérine, méthodes et utilisations pour le traitement de maladies et de troubles neurodégénératifs
EP3086809A4 (fr) Compositions et procédés de traitement de troubles oculaires
EP3082427A4 (fr) Compositions et méthodes destinées à traiter le glaucome
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
EP3265103A4 (fr) Compositions et méthodes de traitement de maladies oculaires
PH12017501694B1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3129054A4 (fr) Méthodes et compositions pour le traitement de maladies et de troubles oculaires
EP3003341A4 (fr) Compositions et méthodes de traitement de maladies rétiniennes dégénératives
EP2999464A4 (fr) Méthodes et compositions destinées à la rupture des biofilms et au traitement des troubles caractérisés par la présence de biofilms
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders